100 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
25 Apr 24
Other Events
8:30am
cell targets Mast cell adjacent targets KIT BLU-808 Monotherapy opportunities to inhibit wtKIT, a primary mast cell target Opportunities for novel … regimens of combination approaches at intersections between therapeutic targets IgE Mast cell histamines cytokines Degranulation prostaglandins tryptase
8-K
EX-99.2
BPMC
Blueprint Medicines Corp
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
D816V Global BLU - 808 Wild - type KIT Additional undisclosed mast cell targets/modalities Building scale in two focused and exciting areas of science 12 … need for an oral therapy that targets core biology Opportunity TKI, tyrosine kinase inhibitor; QoL, quality of life; EU4 includes France, Germany
8-K
EX-99.2
eo4lpb ocqtn
1 Nov 22
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale
8:08am
8-K
y1qsb65rli3j99trnr
30 Jun 22
Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
4:05pm
8-K
EX-99.1
a6b a5684ubq
3 May 22
Blueprint Medicines Reports First Quarter 2022 Results
7:45am